ABSTRACT: Atherosclerosis, an inflammatory lipid-rich plaque disease is perpetuated by the unregulated scavenger-receptormediated uptake of oxidized lipoproteins (oxLDL) in macrophages. Current treatments lack the ability to directly inhibit oxLDL accumulation and foam cell conversion within diseased arteries. In this work, we harness nanotechnology to design and fabricate a new class of nanoparticles (NPs) based on hydrophobic mucic acid cores and amphiphilic shells with the ability to inhibit the uncontrolled uptake of modified lipids in human macrophages. Our results indicate that tailored NP core and shell formulations repress oxLDL internalization via dual complementary mechanisms. Specifically, the most atheroprotective molecules in the NP cores competitively reduced NP-mediated uptake to scavenger receptor A (SRA) and also down-regulated the surface expression of SRA and CD36. Thus, nanoparticles can be designed to switch activated, lipid-scavenging macrophages to antiatherogenic phenotypes, which could be the basis for future antiatherosclerotic therapeutics.
■ INTRODUCTION
Atherosclerosis, defined by persistent inflammation and the buildup of lipid-rich plaques in arterial walls, leads to life threatening cardiovascular conditions such as myocardial infarction, chronic stable angina, and stroke. 1 This inflammation is triggered by high levels of deposited oxidized low density lipoproteins (oxLDL) within arterial walls and contributes to the formation of foam cells, the major constituent of arterial plaque growth. It is well-known that the unregulated cellular uptake of oxLDL by intimal macrophages is primarily mediated through scavenger receptors. 2−6 This cycle is self-perpetuated through unregulated scavenger receptor replenishment and oxLDL uptake. 4 Therefore, new bioactive molecules that can effectively intervene in the uptake of oxLDL via scavenger receptors in a sustained manner can offer a rational approach to manage atherosclerosis and can present potential therapeutic targets for drug discovery. 7−9 Our laboratories have proposed amphiphilic macromolecules (AMs) that competitively bind to cells via scavenger receptors and demonstrate the ability to inhibit uptake of oxLDL in IC21 macrophages, 10, 11 THP-1 monocytes, 12−15 and cell lines engineered with scavenger receptors. 16 The chemical makeup of these AMs comprises a sugar backbone that has been acylated with lauroyl chloride followed by conjugation to 5 kDa poly(ethylene glycol) (PEG). Recently, a study was conducted in which the AM micellar assemblies carrying a cholesterol efflux drug were administered to injured carotid arteries of Sprague−Dawley rats fed a high fat diet. 12 The localized AMs were able to inhibit macrophage retention and decrease cholesterol accumulation in the intima.
Although thermodynamically assembled micelles are promising for the delivery of water insoluble therapeutics, 17−19 such assemblies are vulnerable to disruption (i.e., micelle dissolution) when introduced into a physiological environment. 20, 21 Since micelles are in a constant dynamic equilibrium between the assembled state and unimers (single macromolecules) this can lead to poor drug retention allowing the encapsulated drug and/or unimer to partition into neighboring plasma proteins or lipophilic sinks. 19,22−27 To overcome these challenges, our lab developed AM-based organic nanoparticles, composed of hydrophobic solutes, using a kinetic process known as flash nanoprecipitation (FNP). 28−33 NPs fabricated under this method are resistant to the thermodynamic instabilities of unimer partitioning that are typically associated with thermodynamic micellar formulations. Notably, the NPs composed of an AM shell/corona and a hydrophobically modified mucic acid core (M 12 ) have shown the ability to inhibit oxLDL uptake in human monocyte-derived macrophages (HMDMs), even in the presence of 20% serum, where analogous micellar assemblies were ineffective at that serum concentration. 34 Despite the promise of the AM-based nanoparticles, the antiatherogenic mechanism of action of the NPs remains to be elucidated. Thus, the focus of this work was to utilize bioactive, serum-stable AM-derived NPs and identify the critical macromolecular determinants for regulation of scavenger-receptormediated mechanisms of foam cell formation and atherogenesis. While prevalent pharmacologic factors, such as statins, aim to systematically inhibit the synthesis of cholesterol, approaches capable of managing atherosclerosis through the regulation of scavenger receptor expression may be a more lesion-directed, disease-specific treatment strategy. Insights from our studies indicate that the amphiphilic macromolecule-based nanoparticles have a potent effect not only on competitively inhibiting oxLDL uptake but also switching macrophages to a more inherently antiatherogenic phenotype.
■ EXPERIMENTAL SECTION
Materials. Synthesis of the AMs and of the mucic acid modified with lauroyl chloride (M 12 ) was followed as described previously. 8, 29 Materials used for NP fabrication include tetrahydrofuran (THF) (Sigma-Aldrich), copolymer poly-(styrene 15 -block-ethylene glycol 114 ) (PS 15 PEG; M n = 6600 g/ mol, PDI = 1.10) (Polymer Source), homopolymer polystyrene (PS 14 ; M n = 1500 g/mol) was prepared as described previously, 35 and the hydrophobic fluorophore 2,2,10,10-tetraethyl-6,14-bis(triisopropylsilylethynyl)-1,3,9,11-tetraoxa-dicyclopenta pentacene (EtTP-5) was gifted by Prof. John Anthony from the University of Kentucky, Department of Chemistry (Lexington, KY). Cell culture, blocking assay, flow cytometry, and immunocytochemistry materials include human buffy coats (The Blood Center of NJ), macrophage colony stimulating factor (M-CSF) (PeproTech), RPMI-1640 (ATCC), penicillin/streptomycin (Lonza), Ficoll-Paque premium 1.077g/mL (GE Healthcare), FBS and Hoechst 33342 (Life Technologies), 3,3′-dioctadecyloxacarbocyanine (DiO) labeled oxLDL (Kalen Biomedical), and unlabeled oxidized LDL (Biomedical Technologies Inc.).
Nanoparticle Fabrication and Characterization. Nanoparticles were fabricated via a flash nanoprecipitation process ( Figure 1A ) described previously. 29 Briefly, the shell material, either 100% AM or a combination of M 12 PEG and PS 15 PEG, were dissolved in THF at 40 mg/mL and the core material, M 12 and/or PS 14 , were dissolved at 20 mg/mL, to result in a shell to core weight ratio of 2:1. Five hundred microliters of the THF stream was mixed with 700 μL of the aqueous stream via a confined impinging jet mixer, after which the stream was immediately dispersed into 3.8 mL of picopure water. The NPs were dialyzed 2× against picopure water for removal of the THF. Fluorescent NPs were fabricated by coprecipitating 2.5 wt % core ETtP5 (2,2,10,10-tetraethyl-6,14-bis-(triisopropylsilylethynyl)-1,3,9,11-tetraoxa-dicyclopenta[b,m]-pentacene) 36 with 97.5 wt % core (M 12 and/or PS 14 ). Following dialysis, the NPs were characterized by dynamic light scattering (DLS) using a Malvern-Zetasizer Nano Series DLS detector with a 22 mW He−Ne laser operating at λ = 632.8 nm using general purpose resolution mode. Hydrodynamic diameters (peak size from intensity distribution), and polydispersity indices (PDI) were obtained by diluting the NPs 10-fold in picopure water ( Figure 1C ). The structures of the different amphiphilic shells and hydrophobic cores used for NP fabrication can be found in Figure 1B .
Peripheral Blood Mononuclear Cell Isolation and Culture. Peripheral blood mononuclear cells (PBMCs) were isolated from human buffy coats by Ficoll-Paque (1.077 g/mL) density gradient and ACK lysis of red blood cells as described previously. 29 Cells were washed in PBS, centrifuged at 300g to remove platelets, and added to BD Falcon T175 flasks at a concentration of 2.85 million cells/mL in base media (RPMI 1640 supplemented with 10% FBS and 1% penicillin/ streptomycin). After 24 h of incubation at 37°C and 5% CO 2 , adherent cells were selected and incubated for an additional 7 days in the base media containing 50 ng/mL M-CSF for differentiation into HMDMs. Next, cells were plated into the desired well plate (flow cytometry) or Labtek chamber (microscopy imaging) at a concentration of 150,000 cells/mL and allowed to rest for 24 h before the addition of treatments.
OxLDL Uptake. To evaluate the influence of NPs on oxLDL uptake, HMDMs were incubated with fluorescent DiO oxLDL (1 μg/mL, Kalen Biomedical) and unlabeled oxLDL (4 μg/mL, Biomedical Technologies) with or without NPs (1.5 × 10 −5 M) of each chemistry in base media for 24 h (Figure 2A ). Oxidized LDL with a relative electrophoretic mobility between 1.8 and 2.1 was chosen for these studies as it correlates to a mild to high level of oxidation and is representative of the highly oxidative states of LDL encountered by macrophages in developing plaques. 37 Next, the cells were prepared for analysis on the flow cytometer as described in the scavenger receptor blocking assay. DiO oxLDL fluorescence was quantified via flow cytometry with a FACSCalibur (Becton Dickinson) by collecting 10,000 events per sample and analyzed with Flow Jo software (Treestar) by quantifying the DiO oxLDL MFI. A minimum of three experimental replicates was conducted for this study. Data is presented as % inhibition of oxLDL uptake and determined by the following equation:
= − × %inhibition of oxLDL uptake 100 100 DiO oxLDL MFI of treatment sample DiO oxLDL MFI of oxLDL only control sample Scavenger Receptor-Mediated NP Uptake. To evaluate the influence of blocking agents on NP uptake, HMDMs were incubated with polyinosinic acid (10 μg/mL, Sigma-Aldrich) or CD36 monoclonal antibody (2 μg/mL, clone JC63.1, Cayman Chemical) in base media for 1 h at 37°C. The corresponding isotype control to human CD36 monoclonal antibody, purified mouse IgA, κ (BD Pharmingen, clone M18-254) was included in this experimental protocol to test for nonspecific antibody binding. Following the incubation, blocking agents were removed, cells washed, and then incubated with fluorescent NPs (1.5 × 10 −5 M, 2.5 wt % core ETtP5 with 97.5 wt % core M 12 ) of distinct compositions for 6 h ( Figure 3A) . Next, the cells were prepared for flow cytometry by washing and then incubation with 2 mM EDTA for 15 min on cold packs. After vigorously pipetting each sample the cells were transferred to 5 mL polystyrene tubes, centrifuged at 1000 rpm for 10 min, and then fixed with 1% paraformaldehyde (PFA). NP fluorescence was quantified via flow cytometry with a FACSCalibur (Becton Dickinson) by collecting 10,000 events per sample and analyzed with Flow Jo software (Treestar) by quantifying the Scavenger Receptor Surface Expression. To evaluate the influence of NPs on cell surface scavenger receptor expression, HMDMs were incubated with unlabeled oxLDL (5 μg/mL) with or without NPs of each chemistry for 24 h. Following the incubation, treatments were removed, and cells were prepared for evaluation via flow cytometry or microscopy. For flow cytometry preparation, the cells were washed in blocking buffer (0.5% bovine serum albumin (BSA), 0.1% sodium azide, and 1% normal goat serum in PBS), and incubated with 2 mM EDTA diluted in blocking buffer for 15 min on cold packs. After vigorously pipetting each sample they were transferred to 5 mL polystyrene tubes and centrifuged at 1000 rpm for 10 min. Next, supernatants were decanted, and the cells were incubated for 1 h at 4°C with monoclonal antihuman SR-AI/MSR1-phycoerythrin (PE) antibody (clone 351615, R&D Systems) and APC antihuman CD36 antibody (clone: 5-271, Biolegend) or their corresponding isotype control APC mouse IgG2a, κ (clone: MOPC-173, Biolegend), and mouse IgG2B PE (clone 133303, R&D systems). Following antibody incubation, the cells were washed twice and then fixed with 1% PFA. CD36 APC and SRA-1 PE fluorescence was quantified via flow cytometry with a Gallios (Beckman Coulter) by collecting 10,000 events per sample and analyzed with Flow Jo software (Treestar) by quantifying the MFI of CD36 and SRA-1. A minimum of 3 experimental replicates were conducted for this study. All data were normalized to the basal condition. For microscopy, cells were washed with PBS and then blocked with 0.5% bovine serum albumin (BSA), 0.1% sodium azide, and 10% normal goat serum in PBS for 2 h. Next, cells were incubated for 3 h at 25°C
with monoclonal antihuman SR-AI/MSR1-phycoerythrin (PE) antibody (clone 351615, R&D Systems) and APC antihuman CD36 antibody (clone: 5-271, Biolegend) or their corresponding isotype control APC mouse IgG2α, κ (clone: MOPC-173, Biolegend), and PE mouse IgG2β (clone 133303, R&D systems). Following the incubation they were washed and then incubated with the secondary antibody, goat antimouse IgG2α alexa fluor 488 (SR-A1 conditions) or anti-mouse IgG2β alexa fluor 647 (CD36 conditions) for 1 h. They were then washed, fixed in 4% PFA, and counterstained with Hoechst 33342 before imaging on a Leica TCS SP2 confocal microscope. Figure 3A) . As graded controls of bioactivity, additional NPs were designed and fabricated using differential amounts of nonbioactive shell (PS 15 PEG) and core (PS 14 ) components ( Figure 1B) . To discern the role of the core on NP bioactivity, NPs composed of a nonbioactive shell with different combinations of bioactive and nonbioactive cores were fabricated (top three rows of Figure 1C ), and to discern the role of the shell on NP bioactivity and to identify synergies between the core and shell, NPs composed of a bioactive core with different combinations of bioactive and nonbioactive shells were fabricated (bottom three rows of Figure 1C ). This enables one to deconstruct structure−activity relationships pertaining to the role of the shell versus core at inhibiting oxLDL uptake ( Figure 2B ). In this study, HMDMs were simultaneously exposed to both oxLDL and NPs, and the uptake of oxLDL was evaluated 24 h later via flow cytometry. The results in Figure 2B are from NPs composed of nonbioactive (100% PS 15 PEG) shell formulated with different core combinations of bioactive M 12 and nonbioactive PS 14 , while Figure 2C represents NPs composed of a bioactive (100% M 12 ) core formulated with different shell combinations of M 12 PEG and nonbioactive PS 15 PEG (all NP formulations evaluated are listed in Figure  1C ). One can better understand the importance of the bioactive core, M 12 , by comparing the change in oxLDL inhibition capacity of the nonbioactive shell NPs (100% PS 15 PEG) as the content of M 12 is increased and the content of PS 14 is decreased within the core ( Figure 2B ), which resulted in a 2.8-fold increase in oxLDL uptake-inhibition capacity. However, one can evaluate the importance of the bioactive, M 12 PEG, in the shell by comparing the change in oxLDL uptake-inhibition potential in Figure 2C of the bioactive core NPs (100% M 12 ) as the shell PS 15 PEG content is decreased and the M 12 PEG content is increased (shifting from the 100% PS 15 PEG shell to 100% M 12 PEG shell formulations containing 100% M 12 ), which resulted in a significant but smaller increase in inhibition potential of 1.4-fold. Overall, all M 12 -core containing NP formulations resulted in a significant increase in inhibition potential from the oxLDL control. This was even observed with the nonbioactive 100% PS 15 PEG shell formulation, inhibiting 53% of oxLDL uptake. However, in this same shell formulation, when the bioactive, M 12 , core is replaced with 100% of the nonbioactive, PS 14 core, the oxLDL uptake-inhibition capacity drops markedly to 19%. This level of inhibition is not statistically significant from the oxLDL control. All NP formulations tested revealed to have no toxic effect on the HMDMs (Supporting Information Figure 1) .
Contribution of the NP Shell and Core to Scavenger Receptor Binding. The ability of the NPs to inhibit oxLDL uptake in HMDMs as seen in Figure 2 may be due to competitive binding between the NPs and oxLDL to scavenger receptors. It is well documented that the unregulated uptake of oxLDL is primarily mediated through scavenger receptors such as SRA and CD36. 1−4 Thus, the ability of NPs to bind and be internalized by these receptors on HMDMs was evaluated. The results, presented in Figure 3B ,C, demonstrate that M 12 -core containing NP formulations are internalized via SRA albeit with less internalization via CD36 (Supporting Information Table  1 ). However, it is interesting to note that NP internalization trends via SRA are similar to those via CD36. Between 44 and 59% internalization via SRA was observed for all formulations containing M 12 , but there was no statistical difference in internalization between any of these formulations. Changes in the shell composition did not appear to affect internalization via SRA as long as the M 12 core was present ( Figure 3C ). However, the formulation without a bioactive core or shell, 100% PS 14 core and 100% PS 15 PEG shell, resulted in very low overall cellular internalization (Supporting Information Figure  2 ) and especially via SRA ( Figure 3B ), which is why the histograms in Figure 3D , for this formulation, appear at a lower fluorescence intensity. Significant NP internalization was only observed in the M 12 containing NP formulations (Supporting Information Figure 2 ). The ability of each NP formulation to be internalized via SRA is further represented in the histograms of Figure 3D ,E in which the change in cellular fluorescence attributed to NP uptake via SRA can be identified by comparing the shift from the outlined histogram (NP uptake without SRA blocked) to the solid black histogram (NP uptake with SRA blocked). A further shift of the solid histogram to the left (lower MFI values) indicates a more pronounced effect of SRA blocking on NP uptake.
Effect of NP Shell and Core on Scavenger Receptor Surface and Gene Expression. The presence of scavenger receptors on the surface of plaque-resident macrophages is essential for the unregulated uptake of oxLDL molecules. 1−4 To examine the ability of the different NP formulations to mediate scavenger receptor expression on the surface of the HMDMs in the presence of modified lipids, the expression of SRA-1 (SRA isoform 1) and CD36 was evaluated after cotreatment with different NP formulations and oxLDL ( Figure 4 ). All NP formulations containing 100% M 12 in the core engendered a pronounced decrease in the level of surface expression of SRA (40−49%) and CD36 (52−69%) as compared to the oxLDL control, Figure 4A ,B. A trend can be observed in Figure 4A correlating the level of SRA and CD36 expression with the amount of M 12 in the NP core, with the expression of both scavenger receptors decreasing as the proportion of the M 12 -core composition was increased. As seen with SRA binding, the shell formulation did not have a significant effect on scavenger receptor expression if 100% M 12 core was present ( Figure 4B ). As to be expected, the formulation containing the 100% PS 14 core and 100% PS 15 PEG shell had a minimal effect on CD36 and SRA expression and was insignificant from the oxLDL control ( Figure 4A ). Consistent with surface expression, the 100% M 12 PEG shell 100% M12 core NP formulation caused a down-regulation of mRNA gene expression of both receptors ( Figure 4C) .
A more in-depth assessment of the scavenger receptor phenotype of the HMDMs following NP treatment can be seen in Figure 5A ,B and can be compared to the oxLDL control in Figure 5C . The dark blue area of the pie charts represent highly atherogenic HMDMs that are positive for both SRA and CD36, whereas the lighter two shades of blue represent less atherogenic phenotypes, mid shade representing the population negative for both SRA and CD36, and the lightest shade of blue representing populations positive for only one scavenger receptor. Interestingly, the best NP inhibitor of oxLDL uptake, 100% M 12 PEG shell 100% M 12 core, caused a pronounced shift in scavenger receptor phenotypes by increasing the population of cells negative for both receptors (twice as many as the The proposed mechanism of action by which NPs inhibit oxLDL uptake in HMDMs. Atherosclerosis, influenced by the unregulated uptake of oxLDL, can potentially be inhibited with NP formulations that competitively bind scavenger receptors, become internalized, and cause a decrease in scavenger receptor surface expression, thus leading to a more sustained antiatherogenic phenotype in macrophages. Figure 4B ), whereas treatment with the nonbioactive 100% PS 14 core and 100% PS 15 PEG shell did not alter the HMDM phenotype from that observed with the oxLDL control ( Figures 4A,C) . Images representative of the changes in scavenger receptor expression for each treatment can be seen below each pie chart. While expression of SRA is much less intense than CD36, the images demonstrate that a larger population of the oxLDL and nonbioactive (100% PS 14 core and 100% PS 15 PEG shell) NP treated HMDMs are positive for both scavenger receptors versus the HMDMs treated with the M 12 -core containing formulations.
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■ DISCUSSION
Management of the uncontrolled uptake of oxLDL by cells of actively developing atherosclerotic plaques, primarily macrophages, is a key target for therapeutic drug design and development.
2 Specifically, regulation of the scavenger receptor expression could be an effective strategy to prevent further accumulation of oxLDL and foam cell formation at the site of the atherosclerotic lesions. CD36 and SRA have been demonstrated to play a critical role in atherosclerotic lesion development, modified lipid accumulation, and foam cell formation in a cardiovascular disease mouse model. 38 Herein, we have fabricated a broad sublibrary of NPs to identify the critical macromolecular determinants for regulation of scavenger receptor-mediated mechanisms of foam cell formation and atherogenesis.
The fabrication of a range of NP formulations composed of bioactive and nonbioactive core and shell materials allowed us to discern the roles that the NP core and shell have on these major serial phenomena: SRA mediated-uptake and the regulation of scavenger receptor gene and surface expression, which together are able to repress the uptake of oxLDL. The proposed mechanism of action is depicted in Figure 5D . The core of the NP, composed of the bioactive M 12 , proved to be the most essential component for internalization via SRA and modulating the surface expression of scavenger receptors, SRA and CD36, causing a shift to a less atherogenic cellular phenotype (cells positive for neither or only one of the scavenger receptors vs cells positive for both). However, both the core and shell of the NP demonstrated importance in inhibiting oxLDL uptake, which suggests that they may have distinct yet significant mechanisms of bioactivity.
Upon evaluation of the bioactive shell, M 12 PEG, it is clear that it contributes further to the increase in oxLDL inhibition potential of the NP. However, changes in the shell bioactive component, M 12 PEG, do not appear to have an effect on the NP uptake via SRA or on the regulation of scavenger receptor expression. This suggests that the M 12 PEG shell, in the NP formulation with a M 12 core, is able to inhibit the uptake of oxLDL via alternate mechanisms. The M 12 PEG shell of the NP could allow for additional interactions with the cell (i.e., nonspecific binding to the lipid bilayer 39 ), which would enable the NPs to occupy more of the cell surface and carry out additional oxLDL inhibition. Recent studies in our laboratories using lipid bilayers support this hypothesis of considerable membrane insertion by M 12 PEG.
39
While the amphiphilic shell is integral for stabilization of the hydrophobic core and for enabling cellular interactions, one of the striking new findings of this study is that the core material of the NP plays a more influential role on scavenger receptormediated uptake than the shell. The majority of the NP shell is composed of PEG, a material known to be nonfouling, thus limiting interaction with proteins. 40 The designated length of the PEG coating allows stable transport through physiological fluids but is short enough to allow for exposure of the hydrophobic and electrostatic charge associated with the core-PEG interface as it approaches the cellular membrane with cationic SRA residues. This would allow for electrostatic interactions between the negatively charged NP core and the positively charged surface scavenger receptors and/or the cellular membrane. Alternatively, as the NP approaches the cellular membrane, a portion of the M 12 PEG shell may partition from the NP to the cellular membrane exposing portions of the hydrophobic core. However, this interaction between cellular scavenger receptors and the NP core does not destabilize the NP based on recent work by York et al., who showed that the NPs remain intact with the shell and core components localized, soon after cellular binding and internalization. 34 This type of interaction (i.e., between the hydrophobic NP core and cell surface molecules) has been reported in the literature with some cell types having preferential attachment to hydrophobic polymers. 41 While we have demonstrated in this work that the NPs clearly interact with the HMDMs through SRA-mediated internalization, it is conceivable that there may be an extracellular interaction between the NPs, particularly serum-disrupted NPs, and the oxLDL. However, coincubation studies with NPs and oxLDL suggest that there was no detectable aggregation or increase in NP size (Supporting Information, Figure 3E ). This is to be expected as the NPs are slightly negatively charged (as indicated by the zeta potential in Figure 1C ) and have a PEG shell so any unimer interaction with highly oxidized oxLDL is unlikely since oxLDL itself is negatively charged.
Following scavenger receptor interactions, we hypothesize that the NPs are actively internalized, leading to continued downstream bioactive signaling including scavenger receptor down-regulation. While all M 12 core NPs were readily internalized via SRA, the NPs with more M 12 in the core demonstrated a stronger ability to lower cellular expression of CD36 and SRA, which was sustained for up to 48 h with the most bioactive formulation (Supporting Information Figure  3D ). Not only did the M 12 -core formulations decrease the amount of scavenger receptors on the cell surface but the 100% M 12 PEG shell with 100% M 12 core formulation caused a doubling in the population of cells completely deficient of both key surface scavenger receptors. A shift of this magnitude in the scavenger receptor expression has not been reported before in human macrophages. It was confirmed that the surface receptor down-regulation is not just a factor of NP uptake and receptor depletion but is accompanied by, and is likely caused by, a decrease in the transcription of mRNA responsible for translation of these proteins. To further investigate the potential of NP interactions with oxLDL and this influence on NP bioactivity, scavenger receptor regulation was evaluated in the presence of only NPs. It was observed that scavenger receptor surface and gene expression were down-regulated in HMDMs; demonstrating that this effect is independent of oxLDL-NP interactions (Supporting Information Figure 3B,C) . Figure 3B ).
The NP uptake and down-regulation of cellular scavenger receptor expression correlates strongly with the inhibition of oxLDL uptake. Even with the NP formulation composed of the nonbioactive shell, PS 15 PEG, the presence of the M 12 core was able to increase oxLDL inhibition by 2.8-fold as compared to the nonbioactive PS 14 core. Such effects on scavenger receptor expression have been reported in vitro with smooth muscle cells and macrophages 42, 43 and in vivo with hypercholesterolemic rabbits 44 following treatment with α-tocopherol. The M 12 core NPs evaluated in this work appear to be functioning in a similar manner as α-tocopherol; however, the signaling pathway that α-tocopherol influences to down-regulate CD36 is largely unknown. 42 This consistent bioactivity may be due to the similarities in the chemical structures of α-tocopherol and the lauroyl side chains of the M 12 , which may facilitate hydrophobic interactions. The ability of M 12 core NPs to alter scavenger receptor expression is possibly a concurrent effect of NP binding and blocking of scavenger receptors (providing a protective coating at the cell surface) and downstream intracellular effects including NP internalization and exposure to acidic vesicles in the macrophage. By binding scavenger receptors, the NPs would minimize interactions with oxLDL and disable downstream pathways, which lead to receptor replenishment. NPs that are internalized would likely encounter an enzyme rich environment, which may facilitate the release of M 12 from the NPs, enabling further disruption of receptor replenishment pathways. It is possible that the M 12 may be interfering with the reduction or phosphorylation of transcription factors responsible for upregulation of gene expression or with the PPARγ-dependent nuclear receptor signaling pathway responsible for scavenger receptor replenishment; 37 however, these mechanisms remain to be elucidated. Since oxLDL binding via CD36 has been shown to be a selfperpetuating cycle of unregulated uptake and receptor replenishment, 4 the proposed NP formulations could have two key concerted effects: the disruption of this cycle and a decrease in scavenger receptor access. Furthermore, cholesterol efflux has been linked to the decrease in CD36 expression, 4 again exemplifying the importance of scavenger receptor downregulation for the management of atherosclerosis.
■ CONCLUSIONS
We have advanced a new class of nanotherapeutics that can target macrophage scavenger receptors and repress the receptor atherogenic activity. We have identified the bioactive components of nanoparticles responsible for controlling expression of scavenger receptors, SRA and CD36, involved in the self-perpetuating cycle of unregulated oxLDL uptake and receptor replenishment. The hydrophobic core component of the NPs attenuated both the extracellular interactions of oxLDL with scavenger receptors and the intracellular events that further repress the uptake of oxLDL. A major finding of this study is the ability of bioactive nanoparticles to switch highly atherogenic macrophages to an athero-resistant phenotype, which could be the basis for the emergent design of nanomedicines targeted toward atherosclerotic plaques.
